PSMA-SulfoCy7
PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a Ki of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies.
For research use only. We do not sell to patients.
- CAS No.: 2766510-90-9
- Formula: C90H112ClN13O20S2
- Molecular Weight:1795.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| LNCaP | CC50 |
12.2 μM
Compound: 79; PSMA-SulfoCy7
|
Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human LNCaP cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 33822606] |
PSMA-SulfoCy7 (2 h; 60 min) inhibits PSMA-dependent NAAG hydrolysis in LNCaP cell lysate with a Ki of 18 nM[1].
PSMA-SulfoCy7 is cytotoxic to LNCaP and PC-3 prostate cancer cell lines with CC50 values of 12 μM and 19 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LNCaP and PC-3 prostate cancer cell lines
-
Concentration:CC50
-
Incubation Time:/
-
Result:Inhibited LNCaP and PC-3 prostate cancer cell lines with CC50 values of 12 μM and 19 μM, respectively.
PSMA-SulfoCy7 (i.v.; single dose) exhibits biphasic elimination from blood plasma in rabbits and rats, with elimination half-lives of 1.39 h and 1.78 h, respectively, and primarily distributes to tissues with elimination via the urinary system[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude mice with Prostate cancer (male, 6-8 week-old, prostate cancer xenograft model)[1]
-
Dosage:250 nmol/kg
-
Administration:i.v.; single dose
-
Result:Showed no reliable difference in tumor uptake between 22Rv1 and PC-3 xenografts at 0.5, 1, and 8 h post-injection.
Demonstrated a twofold higher fluorescence signal in 22Rv1 tumors compared to PC-3 tumors at 24 h post-injection.
Showed a significant difference in fluorescence signal between 22Rv1 and PC-3 tumors via ex vivo imaging at 24 h post-injection, with clearer distinction against background tissues.
Chemical Information
-
CAS No. 2766510-90-9
-
Molecular Weight 1795.51
-
Formula C90H112ClN13O20S2
-
SMILES
O=C([C@@H](NC([C@@H](NC(CCC(NCCCCCC(N(CC1=CC(Cl)=CC=C1)CCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O)CC3=CC=C(C=C3)O)NCCCN(N=N4)C=C4CNC(CCCCC[N+](C5=CC=C(C=C5C6(C)C)S(=O)([O-])=O)=C6/C=C/C(CCC/7)=CC7=C\C=C8C(C)(C)C9=CC(S(=O)(O)=O)=CC=C9N/8C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PSMA-SulfoCy7 Related Classifications
HY-D3353 Related Classifications
Powered by Bioz